TPTX News and Press, Turning Point Therapeutics Inc. From 01/23/20

SAN DIEGO, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Garry Nicholson to its board of directors. Mr. Nicholson ...

Repotrectinib Granted Fast Track Designation in Previously Treated ROS1-Positive Advanced Non-Small Cell Lung Cancer Patient Subset; Registrational Phase 2 Study Continues Site Activation and Patient Enrollment Multiple RET-Positive Patients with Solvent-Front Mutations Previously...

SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that Dr. Jean Cui will step down as the company’s chief scientific of...

Quick Take Black Diamond Therapeutics ( BDTX ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The company is developing a platform that identifies small molecule kinase inhibitors, which help to slow or stop cancer. BDTX is a ...

SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Homa Yeganegi as senior vice president, project team leader and head of Medical ...

Investing in IPO stocks  can be fun, but also risky. There can be a scarcity of information about a brand new equity. And sometimes the underwriters intentionally lowball the value of a company, in order to hype the stock (and reward the bank's clients who bought shares on the cheap). None...

SAN DIEGO, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will present a company overview and participate in ...

Arvinas (NASDAQ: ARVN ) initiated with Buy rating and $35 (23% upside) price target at Roth Capital. More news on: Arvinas, Inc., Bicycle Therapeutics plc, Harpoon Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will participate in the Jefferies 2019 London Healt...

SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1/2 clinical study of its lead drug candidate repotrectinib in pediatric p...